-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MZE-829 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MZE-829 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MZE-829 in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Analyst Opinions
Tech, Genes, and Beyond – Startup Transforming Biotech
Biotech Startups Overview Biotech breakthroughs drive cost savings, provide competitive advantages, and showcase efficiency across industries through streamlined manufacturing, custom product development, and resilient supply chains. Biotech advancements are also reshaping the fields of medicine, agriculture, and industry. Startups are leading the way for biotechnology advancements, driven by healthcare demands, government support, and technological breakthroughs. Furthermore, AI integration is driving progress in DNA sequencing, drug discovery, and precision medicine. Meanwhile, ambitious projects such as longevity research and brain-computer interface implants...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MZE-001 in Pompe Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MZE-001 in Pompe Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MZE-001 in Pompe Disease Drug Details:MZE-001 is under development for the treatment of...
-
Product Insights
Matas Homes – MAZE Condominiums Development – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our Matas Homes - MAZE Condominiums Development - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Company Profile
NewThompson Creek Metals Co Inc – Company Profile
Thompson Creek Metals Co Inc (TCM) is a mining and exploration company. The company is engaged in the acquisition, exploration, development, and production of molybdenum, copper, and gold. The company owns and operates Thompson Creek open-pit molybdenum mine and concentrator in Idaho, the US; and Endako molybdenum mine and concentrator and Mount Milligan Mine copper and gold mine in British Columbia Canada. In addition, TMC also owns and operates a metallurgical facility in Pennsylvania, the US. The company also owns...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MZE-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MZE-001 Drug Details MZE-001 is under development for the treatment of Pompe disease. It...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....